Price Alert

Glaukos Corporation (GKOS)

NYSE: GKOS · Real-Time Price · USD

87.39

2.90 (3.43%)

At close: Oct 03, 2025, 3:59 PM

87.41

0.02%

After-hours: Oct 03, 2025, 05:16 PM EDT

3.43% (1D)

Bid	84
Market Cap	5.01B
Revenue (ttm)	432.95M
Net Income (ttm)	-92.79M
EPS (ttm)	-1.61
PE Ratio (ttm)	-54.28
Forward PE	4225.5
Analyst	Buy
Dividends	n/a

Ask	88.5
Volume	713,856
Avg. Volume (20D)	934,315
Open	84.56
Previous Close	84.49
Day's Range	84.03 - 88.37
52-Week Range	77.10 - 163.71
Beta	0.76
Ex-Dividend Date	n/a

About GKOS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GKOS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GKOS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Glaukos Corporation is scheduled to release its earnings on Nov 3, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-8.46%

Glaukos shares are trading lower. The company repo... Unlock content with Pro Subscription

5 months ago

-11.36%

Glaukos shares are trading lower after the company reported Q1 financial results. Additionally, Needham cut its price target on the stock from $176 to $115.

News

1 week ago · businesswire.com

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

1 month ago · zacks.com

Glaukos Builds Dual Growth Engines Amid Market Headwinds

GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.

1 month ago · businesswire.com

Glaukos Announces Participation in Wells Fargo Healthcare Conference

2 months ago · fool.com

Glaukos (GKOS) Q2 Revenue Jumps 30%

Glaukos (GKOS -8.55%), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of...

2 months ago · zacks.com

GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised

Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

2 months ago · seekingalpha.com

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Alex R. Thurman - Senior VP & CFO Christopher William Lewis - Vice President of Investor...

2 months ago · zacks.com

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.52 per share a year ago.